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ABSTRACT
Bloom’s syndrome (BS) is an autosomal recessive
human disorder characterized by genomic instabil-
ity and a predisposition to a wide variety of cancers.
Thegene mutatedinBS,BLM,encodes aproteincon-
taining three domains: an N-terminal domain whose
function remains elusive, a helicase domain charac-
terized by seven ‘signature’ motifs conserved in a
wide range of helicases and a C-terminal extension
that can be further divided into two sub-domains:
RecQ-Ct and HRDC. The RecQ-Ct domain appears
essentialbecausetwopoint-mutationsalteringhighly
conserved cysteine residues within this domain have
been found in BS patients. We report herein that
BLM contains a zinc ion. Modelling studies suggest
that four conserved cysteine residues within the
RecQ-Ct domain coordinate this zinc ion and sub-
sequentmutagenesisstudiesfurtherconfirmthispre-
diction. Biochemical and biophysical studies show
that the ATPase, helicase and DNA binding activities
of the mutants are severely modified. Structural
analysis of both wild-type and mutant proteins reveal
that alteration of cysteine residues does not signific-
antly change the overall conformation. The observed
defects in ATPase and helicase activities were
inferred to result from a compromise of DNA binding.
Our results implicate an important role of this zinc
binding domain in both DNA binding and protein
conformation. They could be pivotal for understand-
ing the molecular basis of BS disease.
INTRODUCTION
Bloom’s syndrome (BS) is a rare, autosomal recessive disease
that results from the mutational inactivation of the human
RecQ family helicase encoded by the BLM gene chromosome
15 (1). Individuals afﬂicted with BS display a pleiotropic array
of syndromes, features associated with pre- and postnatal
growth retardation, sunlight sensitivity, subfertility in females
and infertility in males, immunodeﬁciency, and a marked
predisposition to a variety of cancers, including solid tumours
and leukaemia. Cells from BS patients exhibit a strikingly
high level of chromosomal instability, including chromosome
breakage, translocation, increased rates of sister-chromatid
exchange (SCE) and telomeric association (2–4).
The gene defective in BS encodes the Bloom syndrome
protein (BLM) which consists of 1417 amino acids. It belongs
totheRecQDNAhelicasefamily.Biochemicalanalysisshows
that BLM is a DNA-dependent ATPase and ATP-dependent
DNA helicase that displays a 30–50 polarity (5). DNA helicases
are a class of enzymes implicated in all aspects of DNA meta-
bolism processes including DNA replication, repair, trans-
cription and recombination (6). Consistent with its helicase
function, BLM localizes to some sites of ongoing DNA rep-
lication, particularly during the late S phase or following
replication arrest (7). BLM not only unwinds the canonical
Watson–Crick duplex, but also recognizes and disrupts altern-
ative DNA structures such as the Holliday junction, the triple
helix and the highly stable G-quadruplex structure (8–13).
Besides its helicase domain, BLM contains two conserved
domainsinitsC-terminalregion,namely the HRDC (Helicase,
RNase D Conserved) and RecQ-Ct domains. The HRDC
domain which is distal to the C-terminus may modulate
the helicase function via auxiliary contacts to DNA (14).
The RecQ-Ct (RecQ C-terminal) domain located just after
the conserved seven signature motifs is unique to the RecQ
family of helicases. Although the C-terminal region is devoid
of catalytic activity, it is essential for the maintenance of
chromosomal stability and nucleolar localization in human
cells (15). It is well documented that the BLM helicase per-
forms its diverse functions through protein–protein interac-
tions with a variety of nuclear proteins involved in various
aspects of the DNA metabolism such as BRCA1, ATM,
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doi:10.1093/nar/gki619MLH1, MSH2, MSH6, Rad51, topoisomerase IIIa, replication
protein A, FEN-1 and replication factor C (16–20). Among
these, MLH1, topoisomerase IIIa, Rad51 and FEN-1 interact
with the C-terminal region of BLM. Remarkably, FEN-1
activity is dramatically stimulated by the BLM C-terminal
region containing the RecQ-Ct domain (21).
In this work, we are interested speciﬁcally in the function of
the RecQ-Ct domain due to three independent observations.
First, a sequence homology analysis among the known
members of the RecQ helicase family has identiﬁed a putative
zinc binding domain in the RecQ-Ct domain of BLM (22).
Consistent with this prediction, 3D structure analyses have
revealed the existence of a zinc binding domain in the
RecQ-Ct domain of Escherichia coli RecQ helicase that is
conserved by sequence homology in BLM (23). Second,
two disease-causing BLM missense mutations map to Cys-
1036and Cys-1055(24).These residuesare broadlyconserved
in the RecQ-Ct region of the RecQ helicase family and are
possibly implicated in the zinc binding domain formation.
Third, our previous studies have shown that the zinc binding
domain of E.coli RecQ helicase plays a crucial role in both
DNA binding and protein folding (25). These observations
stimulated us to determine whether the BLM also harbours
a functional zinc binding domain and then to study, in greater
detail, the relationships between the structure and the function
of the zinc binding domain.
Here, we report the biochemical and biophysical character-
ization of the helicase core containing the RecQ-Ct domain of
BLM and that of several mutant derivatives carrying altera-
tions in the four conserved cysteine positions of the zinc bind-
ing motif. We have found that BLM bears a zinc binding
domain that is important for DNA binding, ATPase and hel-
icase activities. Our study provides strong evidence for the
molecular basis of certain missense mutations that cause BS,
gaining insight into both the function of BLM and the mole-
cular basis of BS pathogenicity.
MATERIALS AND METHODS
Materials
4-(2-Pyridylazo)resorcinoldisodiumsalt(PAR),EDTA,DTT,
2-mercaptoethanol, ATP, 5,50-dithiobis-(2-nitrobenzoic acid)
(DTNB) and trypsin were obtained from Sigma. [a-
32P]ATP
was obtained from Amersham Bioscience. Chelex  100 resin
waspurchasedfromBio-Rad.TheN-methylanthraniloylderiv-
atives of adenine nucleotides were synthesized according to
Hiratsuka (26), and puriﬁed on DEAE-cellulose using a gra-
dient of triethylammonium bicarbonate.
Methods
Sequences alignment and theoretical modelling. Comparative
sequence analysis between the helicase core of BLM and
E.coli RecQ was performed with ClustalW (27) and followed
by manual adjustment. For the zinc binding domain region,
where insertions occur, we decided to refer to the multi-
ple alignments shown in Figure 2A, involving eight known
helicases of the RecQ family.
Based on this alignment, we have folded the amino acid
sequence of the helicasecore of BLM onto the template crystal
structure of the apo E.coli RecQ (23) by homology modelling
using MODELLER software (28). The score of 35% identity
between the two sequences was sufﬁciently high to obtain a
realistic model for BLM helicase core. The Zn
2+ ion has been
includedinthemodellingschedule.Themodelhasbeenreﬁned
using the optimize routine of Modeler including molecular
dynamic reﬁnement steps, temperature ranging from 200 to
1000 K. Energy was ﬁnally minimized by the conjugate gradi-
ents optimization method. In the E.coli RecQ, the cysteine res-
idueintheC2positionisstericallyrestrainedbetweenaproline,
oneresiduebefore,andaglycine,oneresidueafterthecysteine.
During the reﬁnement process, it became possible that the
cysteine C2 in BLM model could be included in a small
a-helix ended by a proline residue. This model was easier to
reﬁne than models with a loop in this region. The credibility of
thissecondarystructureelementisreinforcedbythepresenceof
two proline residues in good positions to delimit the a-helix.
The stereochemistry of the ﬁnal model has been checked with
PROCHECK, and its fold has been evaluated using the protein
structureMultiEvaluationtoolinvokingEVAL123D(29),Ver-
if3D (30) and Prosa II (31). Packing quality of the homology
model was also investigated by the calculation of WHATIF
Quality Control Value (32). The results conﬁrmed that a reas-
onable model was obtained. Figure 2B–D were generated with
MOLSCRIPT and rendered with Raster3D. Figure 2E and F
have been drawn with GRASP software (33).
Recombinant proteins. Previous studies have shown that the
RecQ core of BLM consisting of the DEAH, RecQ-Ct and
HRDC domains displays similar enzymatic properties as the
full-size BLM (34). Therefore, the truncated BLM protein
containing residues 642–1290 (BLM
642–1290) and their differ-
ent modiﬁed forms were used in this study. A plasmid for
expression of a truncated form of the helicase core consisting
of the DEAH containing domain, the RecQ-Ct and HRDC
domains (amino acid residues 642–1290) was generated by
inserting the truncated BLM gene between the NdeI and XhoI
cloning sites of the pET15b expression plasmid (Novagen).
In this context, BLM is fused in frame with an N-terminal
peptide containing six tandem histidine residues, and expres-
sion of the His-tagged protein is driven by a T7 RNA poly-
merase promoter. The resulting recombinant plasmid,
pET-BLM
642–1290, was transformed into E.coli BL21-Codon-
Plus (Stratagene). One litre culture of E.coli BL21-CodonPlus/
pET-BLM642–1290 was grown at 37 C in Luria–Bertani
medium containing 50 mg/ml ampicillin and 30 mg/ml chlor-
amphenicol until the A600 reached 0.5. The culture was adjus-
ted to 0.4 mM isopropyl-b-D-thiogalactopyranoside, and the
incubation was continued at 18 C for 20 h. The cells were then
harvested by centrifugation, and the pellet was stored at
 80 C. All subsequent procedures were performed at 4 C.
Thawed bacteria pellets were resuspended in 5 ml of lysis
buffer A [20 mM Tris–HCl, pH 7.9, 500 mM NaCl, 10%
glycerol, 0.1% Triton X-100 and 1 mM phenylmethylsulfonyl
ﬂuoride (PMSF)], and cell lysis was achieved by a French
pressure cell. The lysates were sonicated to reduce viscosity,
and any insoluble material was removed by centrifugation at
13000 r.p.m. with a GA20 rotor from Beckman for 45 min.
The soluble extract was applied to a 20 ml column of nickel-
nitrilotriacetic acid–agarose (Qiagen) that had been equilib-
rated with buffer A. The column was washed with the same
buffer and then eluted stepwise with buffer A containing 50,
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protein was retained on the column and recovered in the 200
mM imidazole eluate. This fraction was further puriﬁed
by FPLC size exclusion chromatography (Superdex 200;
Amersham Bioscience). Following dialysis against buffer B
(20 mM Tris–HCl, pH 7.9, 150 mM NaCl and 10% glycerol),
BLM was stored at  80 C. The protein concentration was
determined by the Bio-Rad dye method with BSA as the
standard.
Site-directed mutagenesis, expression and purification of
mutant proteins. The pET-BLM
642–1290 construct encom-
passing amino acids 642 (nt 1920) to 1290 (nt 3870) was
used as the target plasmid for site-directed mutagenesis. All
point mutations were constructed using recombinant PCR,
with the desired mutations introduced in the internal muta-
genic primers (Table 1). To ensure that only the desired muta-
tion was introduced, the PCR portions were sequenced with
the dideoxy DNA sequencing method. The procedure of the
expression and puriﬁcation of the mutant BLMs is essentially
the same as wild-type protein with the exception that the lysis
buffer A used for mutant proteins contains leupeptin and
pepstatin at 5 mg/ml, respectively. The purity of the BLM
and the mutant proteins were determined by SDS–PAGE ana-
lysis and were found to be >98% (Figure 1).
DNA substrates preparation. PAGE puriﬁed oligonucleotides
listed in Table 1 were purchased from Proligo (France). The 50
and 30 single-stranded DNA (ssDNA) tails of 23mer duplexed
substrateswereformedbyannealingoligonucleotidesAandB,
andusedforbothDNAbindingandhelicaseunwindingexperi-
ments. The duplex DNA substrates were prepared as described
previously (35) with the exception that oligonucleotides used
for ﬂuorescence assays were not 50-
32P-end-labelled. G4 DNA
was prepared and isolated as described (9). Brieﬂy, 250 mM
DNA substrates F21 were denatured in 1· TE containing 1 M
NaCl or1 M KCl by heating at95 Cfor 10 min. The denatured
DNA was then annealed at 37 C for 48 h. The annealed
products were separated on 8% native PAGE containing
10 mM KCl at 4 C for 12 h with constant current of 20 mA.
Bands corresponding to tetrameric G-quadruplex, dimeric
G-quadruplex and monomeric oligonucleotide were identiﬁed
according to their relative mobility by UV-shadowing or auto-
radiography. The identiﬁed bands were then excised from the
gel and eluted with TE (pH 8.0) containing 50 mM NaCl and
20 mM KCl. ThepuriﬁedG-quadruplexDNA wasprecipitated
with ethanol and stored in 10 mM Tris–HCl (pH 7.5).
Quantification of Zn
2+ bound to BLM and mutant BLM
helicases. The Zn
2+ content of BLM
642–1290 and of mutant
Table 1. Sequence of oligonucleotides used for site-directed mutagenesis and DNA substrate
BLM Protein sequences Recombinant or mutagenic PCR primer (50–30)
WT CRXnCXnCDXC F-GGAATTCATATGGAGCGTTTCCAAAGTCTTAGTTTTCCT
R-CCGCTCGAGTTACGATGTCCATTCAGAGTATTTCTGTAA
C1036F FRXnCXnCDXC F-GAAAATATAACGGAATTCAGGAGAATACAGCTT
R-AAGCTGTATTCTCCTGAATTCCGTTATATTTTC
C1036N DRXnCXnCDXC F-GAAAATATAACGGAAAACAGGAGAATACAGCTT
R-AAGCTGTATTCTCCTGTTTTCCGTTATATTTTC
C1055N CRXnNXnCDXC F-TTTAATCCTGATTTTAATAAGAAACACCCAGAT
R-ATCTGGGTGTTTCTTATTAAAATCAGGATTAAA
C1055S CRXnSXnCDXC F-AATCCTGATTTTTCTAAGAAACACCCA
R-TGGGTGTTTCTTAGAAAAATCAGGATT
C1063N CRXnCXnNDXC F-CACCCAGATGTTTCTAATGATAATTGCTGT
R-ACAGCAATTATCATTAGAAACATCTGGGTG
C1055N/C1063N CRXnNXnNDXC F-CACCCAGATGTTTCTAATGATAATGACTGT
R-ACAGTCATTATCATTAGAAACATCTGGGTG
R1037A CAXnCXnCDXC F-AATATAACGGAATGCGCGAGAATACAGCTT
R-AAGCTGTATTCTCGCGCATTCCGTTATATT
D1064A CRXnCXnCAXC F-GATGTTTCTTGTGCTAATTGCTGTTGT
R-ACAACAGCAATTAGCACAAGAAACATC
DNA substrate Length DNA substrate sequences
A 44 GCACTGGCCGTCGTTTTACGGTCGTGACTGGGAAAACCCTGGCG
B 45 TTTTTTTTTTTTTTTTTTTTTTAGCCGTAAAACGACGGCCAGTGC
F21 21 Fluo-GGGTTAGGGTTAGGGTTAGGG
Bold format represents the mutated residues
Figure 1. Analysis of the purified BLM and mutant proteins by SDS PAGE.
The proteins were resolved in 10% SDS–polyacrylamide gel and stained with
Coomassieblue:lane1,C1055N/C1063N(5mg);lane2,C1063N(5mg);lane3,
C1050N (10 mg); and lane 4, BLM
642–12090 (10 mg). The positions of marker
proteins (in kDa) are indicated at the right.
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light at 490 nm when bound to Zn
2+ (36). In order to
more precisely quantify the zinc content of both wild-type
(BLM642–1290) and BLM mutant helicases, all buffers were
treated with Chelex  100 resin. The enzymes were dialysed
against the EDTA-free Chelex -treated buffer, passed over a
10cmcolumnofChelex -100andre-concentrated.Tofacilitate
zincrelease,enzymes( 1nmolinavolumeof40ml)wereﬁrst
denatured with Chelex -treated 7 M guanidine HCl, and then
transferredtoa1mlcuvette.PARwasaddedintothecuvettefor
aﬁnalconcentrationof100mMandthevolumeadjustedto1ml
withbufferB(20mMTris–HClpH8.0and150mMNaCl).The
absorbance was recorded from 350 to 600 nm on a UVIKON
spectrophotometer 941 (Kontron) at 25 C. The quantity of
zinc ion was determined using the absorbance coefﬁcient for
the (PAR)2·Zn
+2 complex (e500 = 6.6 · 10
4 M
 1 cm
 1). As a
control, a solution of 20 mM pure ZnCl2 was quantiﬁed in
the same condition of the samples.
Quantitation of free thiol groups in BLM. Both untreated and
Zn
2+-extracted BLM proteins were subjected to DTNB titra-
tions under native conditions. The enzyme samples were fresh
preparations that had been isolated using buffers to which no
reductant had been added. Any thiol-bearing component of the
cell extracts (either small or macro-molecules) should have
been removed by the chromatography over Ni-NTA and the
exchange (by size-exclusion chromatography or dialysis) of
BLM-bearing column fractions into 20 mM Tris–HCl buffer,
pH 7.9, containing MgCl2 (5 mM), KCl (250 mM), 10% gly-
cerol and EDTA (0.1 mM). The protein concentration ranging
from 4.5 to 15.2 mM, DTNB (20 eq. relative to BLM) was
added as a solution (10 mM) in the same buffer. Control incu-
bations were prepared by adding the same amount of DTNB to
the same buffer (with no protein). The ﬁnal mixtures (400 ml)
were incubated 20–30 min at room temperature, and the inten-
sely yellow dianion of 5-thio-2-nitrobenzoic acid was quan-
tiﬁed by subtracting the A412 nm of the control incubation from
the A412nm of each sample and using an extinction coefﬁcient
of 14150 M
 1cm
 1 (37). These values were converted to
[thiolsfree]. All titrations were performed in duplicate.
Circular dichroism spectroscopy measurements. Circular
dichroism (CD) spectra were recorded on a Jobin-Yvon
Marker IV high sensitivity dichrography linked to a PC
micro-processor. The samples were extensively dialysed
against buffer C (50 mM Tris–HCl, pH 8.9 and 50 mM NaCl)
and were analysed in quartz cells with path lengths of 1 mm.
All spectra were recorded with a 1 nm step, were signal-
averaged over at least four scans and were base-line corrected
by substracting a buffer spectrum. The results were expressed
asmeanresidueellipticity(MRE)indegcm
2dmol
 1deﬁnedas
MRE ¼ qobs mdeg ðÞ =10 · n · Cp · l
where qobs is the CD in millidegree; n, the number of amino
acid residues; l, the pathlength of the cell in centimetres; and
Cp, the molar fraction. The relative content in a-helix was
deduced according to Zhong and Johnson (38): % a-helix =
De222nm · ( 10), where De222nm is the CD per residue at
222 nm and is related to [q]222 by De222nm = [q]222/3300.
A protein concentration of 0.15 mg/ml was used for far-UV
CD measurements.
Size exclusion chromatography. Size exclusion chromato-
graphy was performed at 18 C using an FPLC system
(AKTA, Amersham Bioscience) on aSuperdex 200 (analytical
grade) column equilibrated with elution buffer. Fractions
of 0.5 ml were collected at a ﬂow rate of 0.4 ml/min, and
absorbance was measured at 280 and 260 nm. The Rs values
(Rs designates the Stoke radius of the protein) of wild-type and
mutant BLMs were determined from the plot of log Rs versus
Kav using the different Stokes radii of the standards. The
partition coefﬁcient Kav was calculated using the formula
Kav = (Ve   V0)/(Vt   V0), where Ve is the elution volume
of the sample, V0 is the excluded volume of the column,
Vt is the total volume of the column. The excluded volume,
V0 (7.52 ml) and the total volume, Vt (23.5 ml) were measured
by calibration with Dextran blue and thymidine. The calib-
ration graph of log Rs versus Kav was constructed using
a high and low molecular weight calibration kit from
Sigma: cytochrome c (Mw = 12.4 kDa; Rs = 12 s), carbonic
anhydrase (Mw = 29 kDa; Rs = 22.5 s), albumin (Mw =
67 kDa; Rs = 35.5 s), phosphorylase b (Mw = 97.4 kDa;
Rs = 38.75 s), thyroglobulin (Mw = 669 kDa; Rs = 85 s).
Assuming similar shape factors, the plot calibration of log
Mw versus Kav allowed the determination in ﬁrst approxima-
tion of the molecular weight of the enzyme. Gel ﬁltration
chromatography was performed using a standard elution buf-
fer (50 mM Tris–HCl, pH 7.5, 300 mM NaCl and 0.1 mM
EDTA) with 1 mM ATP and 1 mM Mg(OAc)2. BLM proteins
(5 mM) were incubated in the elution buffer with ATP and
MgCl2 for 2 min prior to injection onto the column.
Protein–DNA binding assay
Electrophoretic mobility shift assay. Protein at concentrations
ranging from 2.5 to 2000 nM was incubated with 2.5 nM
23mer duplexed oligonucleotide labelled at the 50 end using
[g-
32P]ATP and T4 polynucleotide kinase. Incubations were
carried out at room temperature for 20 min in DNA binding
buffer [50 mM Tris–HCl, pH 7.5, 1 mM DTT, 50 mM NaCl
and 10% (v/v) glycerol]. Samples were subsequently subjected
to electrophoresis through a non-denaturing 15% polyacryl-
amide gel [acrylamide to bis-acrylamide, 37.5:1 (w/w)] run in
TBE buffer at 100 V to separate protein–DNA complex from
free DNA. Gels were dried and visualized by autoradiography.
Fluorescence polarization assay. Binding of BLM
642–1290
and its different mutant proteins to DNA was analysed by
ﬂuorescence polarization using a Beacon ﬂuorescence polar-
ization spectrophotometer (PanVera). A 23mer duplexed
oligonucleotide labelled with ﬂuorescein on the 50 end of
one strand was used in this study. Varying amounts of proteins
were added to a 150 ml aliquot of binding buffer (25 mM Tris–
HCl, pH 8, 30 mM sodium chloride, 3 mM magnesium acetate
and 0.1 mM DTT) containing 2 nM of the ﬂuorescein-labelled
DNA. Each sample was allowed to equilibrate in solution
for 5min, after which ﬂuorescence polarization was measured.
A second reading was taken after 10 min, in order to ensure
that the mixture had equilibrated. Less than 5% change was
observed between the 5 min measurement and the 10 min
measurement indicating that equilibrium was reached. The
equilibrium dissociation constant was determined by plotting
polarization as a function of protein concentration and ﬁtting
the data to the Michaelis–Menten or Hill equation by using
the program KaleidaGraph (Synergy Software).
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measure of the radioactive g-
32Pi liberated during hydrolysis
(39). Brieﬂy, the measurement was carried out at 25 or 37 Ci n
a reaction mixture containing 1.5 mM (nt) heat-denatured
HindIII-cut pGEM-7Zf linear DNA at the indicated concen-
tration of ATP. The reactions were initiated by the addition
of BLM helicase into a 100 ml reaction mixture and stopped
by pipetting 80 ml aliquots from the reaction mixture every
30 s into a hydrochloric solution of ammonium molybdate.
The liberated radioactive g-
32Pi was extracted with a solution
of 2-butanol (C4H10O)/benzene (C6H6)/acetone (C3H6O)/
ammonium molybdate [(NH4)6Mo7O24, 150 mM]
(750:750:15:1) saturated with water. An aliquot of the organic
phase was counted in 6 ml of Aquasol.
ATP binding assays. The UV cross-linking assay was ﬁrst used
to assess the ATP binding ability of both wild-type and mutant
BLM proteins (40). One microgram of wild-type or mutant
helicase proteins were premixed in 10 ml of a buffer containing
20 mM HEPES–KOH, pH 7.5 and 5 mM Mg(CH3CO2)2. Then
2.5 mCi (2 pmol) of [g-
32P]ATP (3000 Ci/mmol; Amersham)
and 150 pmol of cold ATP were added. The reaction mixture
was incubated on ice for 15 min and was then irradiated using
a UV cross-linker (Stratagene) (254 nm) situated at a dis-
tance of 4 cm for 5 min. Samples were boiled in sample buffer
(100mMTris–HCl, pH6.8,2%SDS,20%b-mercaptoethanol,
20% glycerol, 4 mM EDTA and 0.01% bromophenol blue)
for 5 min and were then separated by SDS–12.5% PAGE. The
gels were stained with Coomassie brilliant blue, dried and
processed for autoradiography.
Fluorescence measurements. The above UV cross-linking
assay is a non-equilibrium method of measuring ATP binding
and cannot be used to determine the apparent dissociation
value. We therefore used a ﬂuorescent nucleotide analogue
(mantATP) to determine the apparent dissociation values
between the wild type and mutants. Fluorescence spectra
were measured using a PiStar-180 spectrometer (Applied
Photophysics) or a Fluoro Max-2 spectroﬂuorimeter (Jobin
Yvon, Spex Instruments S.A., Inc.) at 25 C. In a 10 · 10 · 40
quartz cuvette, 0.5 mM protein in 1 ml reaction buffer was
excited at 280 nm and ﬂuorescence emission was monitored
at 350 nm. MantATP binding to protein was measured by
exciting BLM proteins at 280 nm and measuring the ﬂuores-
cence of mantATP at 440 nm due to FRET. Both sample
dilution and inner ﬁlter effects were taken into account and
the observed ﬂuorescence intensity was corrected (41).
The apparent Kd values were determined by ﬁtting the
ﬂuorescence intensity values to the following equation:
F ¼ Fs þ f dx þ f c
x þ 0:5 þ Kd ðÞ  
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
x þ 0:5 þ Kd ðÞ
2 2x
q
2
‚
1
where Fs is the starting ﬂuorescence of the reaction mixture;
fd, the ﬂuorescence coefﬁcient of free mantATP; fc, the ﬂuor-
escence coefﬁcient of complex formed; x, the total concentra-
tion of mantATP and Kd, the apparent constant dissociation.
Helicase assay
Radiometric helicase assay. DNA helicase activity was
measured in reaction mixtures (15 ml) containing 25 mM
HEPES–NaOH, pH 7.5, 25 mM CH3CO2Na, 7.5 mM
(CH3CO2)2Mg, 2 mM ATP, 1 mM DTT, 0.1 mg/ml BSA,
the indicated 32P-labelled partial duplex DNA substrate
(10 fmol, 3000 c.p.m./fmol) and enzyme fraction. After
incubation at 37 C for 20 min, 4 mlo f5 · loading buffer
(50 mM EDTA, 0.5% SDS, 0.1% xylene cyanol, 0.1% bro-
mophenol blue and 50% glycerol) was added, and aliquots
were loaded onto a 12% polyacrylamide gel containing
0.1% SDS in 1· TBE (90 mM Tris, 90 mM boric acid and
1 mM EDTA, pH 8.3) and electrophoresed for 1.5 h at 150 V.
Fluoromertic helicase kinetic assay. An unwinding assay
was performed using a Beacon 2000 polarization instrument,
according to Xu et al. (42). An appropriate quantity of
ﬂuorescein-labelled duplex oligonucleotide was added to the
helicase unwinding buffer (150 ml total) in a temperature-
controlled cuvette. The anisotropy was measured successively
until it stabilized. The helicases were then added into the
reaction tube. When the higher anisotropy value became
stable, the unwinding reaction was initiated by the rapid
addition of ATP solution to give a ﬁnal concentration of
1 mM. The decrease of the anisotropy was recorded every
8 s until it became stable. The unwinding buffer contained
25 mM Tris–HCl (pH 8.0), 30 mM NaCl, 3 mM
(CH3CO2)2Mg and 0.1 mM DTT.
RESULTS
We used a wide array of biochemical and biophysical
methods, including structural modelling and site-directed
mutagenesis, to better understand and deﬁne the function of
the zinc binding domain in the BS protein. Conventional gel-
based assays allowed to qualitatively assess the helicase and
DNA binding activities. The related parameters were further
determined quantitatively by ﬂuorometric measurements. The
combination of these approaches enabled us to analyse the role
of the zinc binding domain in precise detail.
Homology modelling predicts a zinc binding
domain in BLM
The ﬁnal alignment of the sequences of the helicase core
from BLM and from E.coli RecQ helicase showed that 35%
of the residues are identical and 20% highly similar. In the zinc
bindingdomainregion,wetookintoaccount8RecQsequences
(Figure 2A) with all the residues known to be conserved
throughevolution(25)perfectlyaligned.Thescoreofsequence
identity between the BLM and E.coli RecQ sequences, largely
above the well-established limit of 30% (28), allowed us to
obtain a realistic model for the 3D structure of the BLM hel-
icase core (Figure 2B) starting from the crystal structure of
E.coliRecQhelicaseasatemplate.Sincethetemplatestructure
does not contain the HRDC domain, we only modelled the
BLM helicase core Phe-644 to Ser-1195 of the enzyme tested
for function (residues 642–1290). Thus, our model does not
include the HRDC domain present in the BLM construct used
in biochemical studies. The stereochemistry, energy and pack-
ing quality tests applied conﬁrmed that a reasonable model
was obtained, suitable to investigate the zinc binding motif
and to explore the role of different conserved residues.
The modelled BLM helicase core comprises 36 residues
more than the catalytic core of E.coli RecQ helicase. Almost
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portion of the model. More precisely, 16 residues are in the
C-terminus, 10 are in the zinc binding domain and 10 residues
are in the N-terminus. The enzyme is folded in four distinct
domains, including a characteristic zinc binding domain. The
root mean square deviation (RMSD) between the RecQ back-
bones from E.coli and from the BS protein is 0.7 s for 516 Ca
atoms, the C-terminal region showing the most signiﬁcant
differences (Figure 2B). The overall topology of the zinc bind-
ing domain conforms to the expected fold of a classical C4
zinc binding domain which is composed of the four conserved
cysteines: Cys-1036, Cys-1055, Cys-1063 and Cys-1066
(labelled C1–C4) bound to a single zinc ion (Figure 2C). In
BLM, the zinc binding domain comprises 10 residues more
than in E.coli (Figure 2A, C and D). They are divided into
three main insertions (in orange in Figure 2C), the longer one
between C2 and C3. Cys-1036 is in the conserved helix equi-
valent to a17 in RecQ model; Cys-1063 and Cys-1066 are
located in the conserved helix equivalent to a18 in the
RecQ model, in red in Figure 2C. The main differences appear
in the region of the Cys-1055 residue (C2). Cys-1055 is loc-
ated in a short a-helix, in violet in Figure 2C, situated between
the helices equivalent to a17 and a18 in the RecQ structure.
The restraint imposed by the proline and glycine residues
surrounding C2 in the E.coli enzyme for positioning the
cysteine side chain (Figure 2D) could be replaced by one
helix in the BLM (in violet in Figure 2C). Due to this addi-
tional secondary structure element, it appears that all the cys-
teineresiduesboundtotheZn
2+ionare includedintoa-helices
in the human enzyme. It is worth noting that two disease-
associated mutations are found in the zinc binding domain.
These mutations (indicated by # characters in Figure 2C) are
C1036F at C1 position and C1055S at C2 position.
As in the RecQ template structure, the conformation of the
BLM zinc binding domain is obviously stabilized through
three hydrogen bonds (Figure 2C and D) between NE Arg-
1037 and OD1 Asp-1064, NH2 Arg-1037 and OD2 Asp-1064,
and between NH1 Arg-1037 and the main chain atom O of
Tyr-1029, involving highly conserved residues in the RecQ
family (Figure 2A). Arg-1037 is one residue after C1, and
Asp-1064 is one residue after C3 whereas the equivalent of
Tyr-1029 is always a tyrosine or phenylalanine positioned
before C1. These three residues, involved in three hydrogen
bonds, contribute efﬁciently to the relative positioning of the
a-helices of the zinc binding domain and thus appear to be
important for the fold of this motif.
Interestingly, both zinc binding domains of BLM and E.coli
RecQ helicase exhibit similar positively charged electrostatic
surfaces (Figure 2E and F). It can be hypothesized that these
positively charged regions could be involved in protein–
protein or protein–DNA interactions (43).
Confirmation that BLM is a zinc-containing protein
To determine whether BLM binds a zinc ion, the zinc content
ofthe puriﬁedhelicasecore ofBLM wasmeasured using PAR.
As shown in Figure 3A, the increase in absorbance at 500 nm
following BLM addition to a solution containing PAR indic-
ates the formation of a PAR2Zn
2+ complex. Quantitative ana-
lysis of the amounts of zinc atom associated with the puriﬁed
BLM indicated that the zinc atom binds to BLM in a stoi-
chiometric ratio (Table 2). This observation was further con-
ﬁrmed by the existence of a linear correlation between the
amount of zinc ion and the increasing concentration of the
protein (Figure 3B). The slope value of 0.98 – 0.11 indicates
that each molecule of BLM contains one zinc ion. We then
compared the number of solvent-accessible thiol groups
between the full zinc-metalated and zinc-demetalated BLM.
For this purpose, the zinc atom was removed from wild-type
BLM by EDTA extraction (21). It is referred to, hereafter, as
zinc-demetalated BLM helicase. With this EDTA extraction
method, the content of the zinc atom of the zinc-demetalated
BLM was reduced to 0.15–0.20 mol/mol enzyme. The
results show that zinc-demetalated BLM has 2.85–3.12 addi-
tional solvent-accessible thiol groups. Considering the fact
that the zinc extraction is incomplete and the presence of
the inevitable partially oxidized protein, the above results
are consistent with a zinc atom binding site being formed
by four cysteines. These studies clearly show, in accordance
with the modelled structure, that BLM carries a zinc
binding domain.
Effect of the zinc ions on BLM enzymatic activities and
on the conformational stability of the protein
The next question was whether the zinc ion binding to this
proteinisnecessaryfortheDNAbinding,ATPaseandhelicase
Figure 2. Modelled structure of the BLM helicase core and details of the sequence alignment. (A) Amino acid sequence alignment of the conserved putative zinc
binding domain among the RecQ family helicases. The multiple alignments were performed with the program ClustalW and refined manually. The numbers at the
beginningandtheendofeachsequencecorrespondrespectivelytothepositionsofthefirstandthelastaminoacidresidues.Highlyconservedaminoacidresiduesare
shadowed in grey. In red are the four conserved cysteine residues, labelled C1–C4, and, in blue, the fully conserved arginine, aspartic acid and aromatic residues,
involved in three very important hydrogen bonds shown in (C). The consensus sequence was generated by ClustalW. The protein accession numbers used by the
National Center for Biotechnology Information are RecQ, P15043 (E.coli); SgS1, P35187 (S.serevisiae); Rqh1, Q09811 (Schizosaccharomyces pombe); RecQL1,
NP_002898/P46063 (Homo sapiens); WRN, NP_000544/Q14191 (H.sapiens); BLM, A57570/P54132 (H.sapiens); DmBLM, Q9VGI8 (H.sapiens); RECQL5,
Q9BW80(H.sapiens).SecondarystructureelementsofRecQappearwithboxesdesigningthea-helicesofthezincbindingdomain.(B)StereoviewoftheCatraceof
the RecQ catalytic core from BS Protein (mauve), as obtained after refinement of the structure generated by the Modeller computation (see text for details) and
superimposed with the catalytic core of E.coli RecQ (magenta) that served as template in the modelling. The root mean square deviation (RMSD) between the two
structuresis0.7sfor516Caatoms.Thezincionisincyan.(C)RibbondrawingofthezincbindingdomainofthemodelledBLMhelicasecore.Thezincionisincyan.
Conserveda-helicesaredrawninredwhereasthethreemaininsertions,comparedwithsequencefromE.coli,arefiguredinorange.ThemodelledhelixincludingC2is
drawn in violet. As in the alignmentshown in (A), the positionsof the four totally conserved cysteine residues are labelled as C1–C4. The fully conserved arginine,
asparticacidandaromaticresidues,involvedinthreeveryimportanthydrogen-bonds(dashedlines)stabilizingtheconformationofthezincbindingdomain,areshown
in ball and stick representation. (D) Ribbon drawing of the zinc binding domain in the crystal structure of the E.coli RecQ (PDB ID:1OWY). Colour codes and
orientationarethesameasin(C).Inballandstickareresiduesimportantforthestructureandthefunctionoftheenzyme.(E)Grasppotentialsurfaceofthemodelled
BLMzincbindingdomaininapproximatelythesameorientationasin(C).Themolecularsurfaceiscolouredbytheelectrostaticpotential:blue,positive;red,negative;
white,neutraland itis superimposedon the polypeptide chain.The Zn ionis in blueand C1–C4cysteineresidues appearin stickrepresentation. (F) Grasppotential
surfaceofE.colizincbindingdomaininthesameorientationasin (D).Themolecularsurfaceis colouredbytheelectrostaticpotential:blue,positive;red,negative;
white, neutral and it is superimposed on the polypeptide chain. The Zn ion is in blue and C1–C4 cysteine residues appear in stick representation.
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wild type with that of the zinc-demetalated BLM helicase
showed that BLM helicase can still hydrolyze ATP, bind
DNA and unwind duplex DNA substrate in the absence of
zinc ion. Parameters such as kcat and Km for ATPase and
helicase activities display essentially the same values for the
wild-type and zinc-demetalated enzymes (Table 2). The effect
of the zinc atom on the enzymatic properties of wild-type and
zinc-demetalated proteins was further evaluated with increas-
ing zinc concentration. We found that the zinc ions only mod-
estly affect ATPase activity of BLM (results not shown). Since
the above observations might indicate that the zinc ion does
not play an essential role in catalysis, we further investigated
whether the zinc ion is important for the stability of BLM.
This possible stabilization effect was substantiated by meas-
uring ATPase activity at different temperatures. As shown
in Figure 4A, the kcat values of the zinc-demetalated BLM
are systematically lower than that of the zinc-containing BLM,
indicating that the zinc ion can enhance the thermostability of
BLM. To conﬁrm whether zinc stabilizes the conformation of
BLM, we performed limited proteolysis on both heat-treated
zinc-containingandzinc-demetalatedBLMs.Figure4Bshows,
in agreement with the thermostability experiments, that the
zinc-demetalated BLM is less resistant to proteases than
the zinc-containing BLM. Collectively, these results establish
that the zinc ion is not implicated in catalysis, but plays an
essential role in maintaining the stability of the 3D structure of
the protein.
Characterization of BLM mutant proteins
Site-directed mutagenesis was used to elucidate the functional
signiﬁcance of the zinc binding domain. The design of muta-
tionswasbasedonthreeaspectsofthestructuralandfunctional
properties of BLM. First, according to molecular modelling,
four cysteine residues are implicated in the zinc binding
domain. Three of the four cysteine residues were therefore
replaced by other residues. We attempted initially to make
a panel of substitutions in which the four conserved cysteines
would be replaced by four alanine or serine residues, but
despite several attempts, we were not successful at generating
these modiﬁed BLM proteins since these mutants appear to be
degraded totally before the puriﬁcation step even in the pres-
ence of protease inhibitors (PMSF, leupeptin and pepstatin). In
contrast, mutant proteins with one or both positions at C2 and
Table 2. Properties of wild-type and mutated BLM proteins
Protein Proteins Zinc
b ATPase activity (s
 1) Helicase activity DNA binding (nM) ATP binding (mM) Rs
c (A ˚)
state
a kcat kwt
cat=kmut
cat Km (mM) kmut
m =kwt
m kcat kwt
cat=kmut
cat KdsDNA
d KG4DNA
d Kd (mM)
WT S 0.98 26.48 1 88 1 2.5 · 10
 2 1.00 29.8 – 1.3 4.57 50.26 – 0.71 34.57
WT
zn  S 0.18 28.56 0.95 79 1 2.6 · 10
 2 0.96 30.5 – 2.5 4.85 52.3 – 0.95 33.87
C1055N S 0.50 1.15 22.95 938.5 10.61 0.9 · 10
 2 2.7 56 – 1.8 400 78.65 – 6.5 33.98
C1063N S 0.52 2.16 12.26 3149 35.57 5.4 · 10
 4 46.3 124 – 2.3 1986 64.47 – 1.9 34.69
C1055N/C1063N S 0.01 4.26 6.21 6648 75.07 9.9 · 10
 4 25.5 209 – 3.5 3.28 · 10
15 100.6 – 3.7 34.94
C1036F I ND
d
C1055S D ND
R1037A I ND
aS, D and I represent soluble protein, degraded protein and protein in the form of inclusion bodies.
bThese values represent the number of zinc ion per molecule of protein.
cRs represent Stokes radii.
dND, non determined.
Figure 3. (A) Absorbance spectra of wild-type and mutant BLMs in the pre-
sence of PAR. Enzymes (1 nmol for wild-type and each mutant proteins)
were prepared as indicated under Materials and Methods and were added to
a 1 ml cuvette containing 100 mM PAR in Chelex 100-treated 50 mM Tris
and 100 mM NaCl, pH 7.8. The spectra were scanned from 300 to 600 nm. As
a control, 20 nmol ZnCl2 was added and scanned in the same conditions. All
assays were run at room temperature (25 C). From top to bottom: ZnCl2, wild
type, C1055N, C1063N, C1055N/C1063N and buffer alone. Inset: a typical
absorbancespectraofPARintheabsenceandinthepresenceofZnCl2.(B)Zinc
ion quantity was determined as increasing concentration of the protein. The
slope value of 0.98 determined from this figure indicates that the zinc atom
binds to BLM protein in a stoichiometric ratio.
3116 Nucleic Acids Research, 2005, Vol. 33, No. 10C3 replaced by asparagine were puriﬁed to homogeneity.Their
ability to bind zinc was therefore assessed under the same
experimental conditions, as the wild-type enzyme. While
0.95 mol of zinc ion was bound to 1 mol of the wild-type
enzyme, only 0.50, 0.52 and 0.01 mol zinc ion was bound
to the mutants C1055N, C1063N and to the double mutant
C1055N/C1063N, respectively (Table 2). Second, the mod-
elled structure suggests that Arg-1037, Asp-1064 and
Tyr-1029 could be involved in hydrogen bonds, and could
contribute to the stabilization of the zinc motif. We therefore
investigated the role of these residues in the stabilization of
the protein conformation. In fact, a previous study has shown
that replacement of D1064 by alanine severely impaired
the helicase and DNA binding activities (34). We thus specu-
lated that the mutant R1037A could display similar properties
as the mutant D1064A. Surprisingly, the resulting mutant
R1037A was completely degraded before puriﬁcation, pre-
venting its study. These results indicate that both Arg-1037
and Asp-1064 stabilize the structure of the zinc binding
domain and of the whole protein, a topic that will be further
discussed in the Discussion. Third, two point mutations
C1055S and C1036F have been previously identiﬁed in
human BS patients (20,22). To understand the impact of
these residues on the zinc binding domain together with the
molecular and structural basis of this disease, Cys-1055 was
replacedby serine and Cys-1036was replaced by phenylanine,
respectively. The resulting mutants either displayed a high
level of susceptibility to degradation (C1055S) or formed
inclusion bodies (C1036F) (Table 2), making it impossible
to purify the proteins for further analysis.
These results, taken together, indicate that BLM contains a
functional zinc motif that coordinates a single, tetrahedral
Zn
2+ ion using the four conserved cysteines. The zinc binding
domain could be further stabilized by hydrogen bonds formed
between Y1029 and R1037 and between R1037 and D1064.
The zinc binding domain is required for ATPase and
helicase activities
The functional signiﬁcance of the zinc binding motif was
assessed by measuring ATPase and helicase activities of the
wild-type and mutant proteins. ATPase activity was measured
in the presence of DNA to stimulate the ATP hydrolysis activ-
ity of BLM. While the wild-type protein displayed an ATPase
activity that remains comparable with the previous determina-
tion(35s
 1),thisactivitywasseverelymodiﬁed forthemutant
proteins (Figure 5). Compared with wild-type enzyme, the kcat
values for mutant proteins decreased from 6- to 25-fold, and
the Km values increased from 10- to 74-fold.
The helicase activityof wild-type and of the mutant proteins
were analysed on a partial DNA duplex substrate comprising a
Figure 4. (A) ATPase activity of BLM
642–1290 and zinc-demetalated
BLM
642–1290 as a function of temperature. ATPase activity was assayed in
the presence of 10 nM BLM with increasing concentration of ATP at the
indicated temperatures. The experimental data were analysed according to
the Michaelis–Menten equation, and the apparent kcat and Km values were
determined from the best fit. (B) Limited proteolysis of BLM and zinc deme-
talatedBLM.BothBLM(lanes1and4)andzincdemetalatedBLM(lanes2and
5)(15mgforeachprotein)wereincubatedat48 C for5min,andweredigested
with 0.065% (lanes 1 and 2) and 0.12% (lanes 4 and 5) trypsin (w/v) at 4 C for
3 min. The reaction was stopped by addition of PMSF to a final concentration
of 10 mM. The samples were separated by SDS–PAGE and stained with
Coomassie blue. Lane 3 is BLM control (10 mg, not heat-treated, not digested).
Figure 5. ATPhydrolysisactivityofwild-typeand mutantBLMsasa function
of ATP concentrations. Experiments were performed in ATPase assay buffer
(25mMTris–HCl;35 mMNaCl;0.5 mMDTTand3mMMgCl2)at37  Cwith
6 mM ssDNA (nt, 60mer oligonucleotide) and 10 nM protein for each enzyme.
TheATPhydrolysiswasquantifiedasdescribedinMaterialsandMethods.The
lines correspond to the fits to a Michaelis–Menten equation for wt (circle),
C1063N mutant (triangle), C1055N (square) and C1055N/C1063N (rhombus).
The apparent kcat and Km values are presented in Table 2.
Nucleic Acids Research, 2005, Vol. 33, No. 10 311744mer radiolabelled oligonucleotide annealed to a 45mer oli-
gonucleotide. This substrate was incubated with increasing
amounts of BLMs in the presence of ATP, followed by
analysis of the reaction products on a non-denaturing 15%
polyacrylamide gel. Results given in Figure 6A indicate that
the mutant proteins do not or poorly unwind DNA substrates.
This led us to determine the apparent kcat values of helicases
using a ﬂuorescence assay under equilibrium conditions.
Figure 6. (A) DNA helicase activity of BLM
642–1290 and mutant proteins revealed by radiometric assay. 50-
32P-labelled DNA substratewas incubated at 30 C with
BLM
642–1290anddifferentpointmutantsinthehelicaseassaybuffer.Thereactionswereterminatedafter30minandthesampleswereanalysedbyelectrophoresisin
a10%non-denaturingpolyacrylamidegel.Theconcentrationsoftheproteinsrangefrom1.25to160nM.TheHrepresentstheheat-denaturedsubstratecontrol,and
the C represents the BLM642–1290 enzyme control. (B) Kinetic analyses of DNA unwinding by wild-type BLM (circle) and mutant proteins (triangle, C1055N;
rhombus, C1063N; square, C1055N/C1063N) using a fluorometric assay. Helicase reaction mixtures contained 1 nM partial duplex DNA substrate in unwinding
buffer. DNA unwinding was initiated with addition of 1 mM ATP at 25 C. Data from the time courses were fitted to the exponential equation: At = A exp( kobst),
where At is the anisotropy amplitude at time t, and kobs is the observed rate constant. These data are summarized in Table 2.
3118 Nucleic Acids Research, 2005, Vol. 33, No. 10Figure 6B shows that, consistent with the previous results
obtained with the gel shift method, the mutants C1050N
and C1063N display only very weak helicase activities. The
kcat values were decreased to 35- and 74-fold for the mutant
C1055N and the mutant C1063N, respectively. Surprisingly,
the kcat value for the mutant C1055N/C1063N was only
decreased 3-fold compared to that of wild-type enzyme.
These results, collectively, indicate that the zinc binding
domain is crucial to ATPase and helicase activity of BLM.
Mutation of cysteine residues implicated in the zinc
binding domain does not affect ATP binding
To further improve our understanding on the role of the zinc
binding domain in BLM, ATP binding by the wild-type and
mutant proteins was examined by UV cross-linking, as pre-
viously reported (29). Both puriﬁed wild-type and mutant
proteins were incubated with [g-
32P]ATP. The mixtures
were subsequently cross-linked via UV light. Proteins that
display ATP binding activity are covalently bound to ATP
and thus become radiolabelled. Both wild-type and mutant
helicase proteins were efﬁciently labelled, as illustrated in
Figure 7A. No radioactivity was observed, however, if the
mixture was not exposed to UV light or if BSA protein was
used in place of the helicase protein, thus revealing speciﬁc
binding of ATP to the helicase protein. However, this is a
non-equilibrium method. We therefore studied ATP binding
quantitatively using mantATP as a ﬂuorescent ATP analogue
under equilibrium conditions. Mant-nucleotides are widely
used with many NTPases for investigating nucleotide binding
because the spectral properties of mant-ﬂuorescence are ide-
ally suited for monitoring nucleotide binding by FRET
(23,30). We ﬁrst conﬁrmed that the emission spectrum of
BLM overlaps with the excitation spectrum of the mantATP,
indicating the possibility of performing FRET (Figure 7B).
The apparent association constant values (Kd) of mantATP
for wild-type and mutant proteins were determined over
increasing concentrations of mantATP (Figure 7C). The val-
ues for the wild-type and mutant proteins were found to be
similar (Table 2). This study shows therefore that the zinc ion
and the zinc binding domain are not required for ATP binding.
Structural characterization of the mutant proteins
To determine whether the mutations induce a change in pro-
tein conformation, and consequently affect its activity, we
characterized some of the structural properties of the mutant
enzymes with two different approaches. Far-UV CD was ﬁrst
usedtoanalyse thesecondary structure oftheproteins.TheCD
spectra of both wild-type and mutant proteins show a max-
imum at  200 nm and two strong minima at 208 and 222 nm,
characteristic of a-helical structures (Figure 8A). Analysis of
the CD spectra using % a-helices =D e 222nm · ( 10) indicate
that wild-type BLM contains  51.1% a-helical structure, in
agreement with the secondary structure predictiondata (50.5%
a-helices, see Supplementary Material). The three mutant pro-
teins displayed only a modest reduction in a-helices content,
presenting 50.9, 50.3 and 48.5% a-helical structure for
C1055N, C1063N and C1055N/C1063N, respectively. Thus,
the replacement of one cysteine residue within the zinc bind-
ing domain does not produce signiﬁcant change in the
Figure 7. (A) ATP bindingactivityof the wild-type(BLM
642–1290) and mutant
BLMs. One microgram of the wild-type or mutant helicase protein was
incubated with [g-32P]ATP in the presence of ssDNA (60 base) and was UV
cross-linked as described under Materials and Methods. Samples were sepa-
ratedbySDS–8%PAGE.Followingelectrophoresis,thegelswerestainedwith
Coomassie brillant blue, dried and processed for autoradiography. WT, wild-
type BLM (BLM
642–1290); WT ( UV), wild-type enzyme not exposed to UV;
BSA, bovine serum albumin. (B) The overlap of the BLM emission spectrum
(lex = 280 nm) and the mantATP excitation spectrum (lem = 440 nm). The
excitationwavelengthforthemantATPemissionspectrumislex = 345nm.For
thereasonofclarity,onlywild-typeBLMproteinexcitation-emissionspectrum
is shown. (C) Changes in fluorescence intensity when 0.5 mM wild-type (open
squares), and mutant proteins (C1055N, closed circle; C1063N, closed square;
open circle, C1055N/C1063N) were titrated with increasing concentration of
mantATP. Solid lines represent the best fit of the data to Equation 1 and the
apparentKdvaluesaresummarizedinTable2.MolecularstructureofmantATP
is shown in the insert.
Nucleic Acids Research, 2005, Vol. 33, No. 10 3119secondary structure of the BLM protein as judged from the CD
spectra.
Size exclusion chromatography was used to determine the
Stokes radius of wild-type and mutant proteins. Figure 8B
shows that both wild-type and mutant proteins were found
to elute in a single peak corresponding to a molecular mass
of 71600 Da, a value close to the predicted molecular mass
(74.1 kDa). These results not only conﬁrm that BLM and its
modiﬁed versions exist as a monomer in solution, but also
reveal that the Stokes radius values of the wild-type and mut-
ant proteins are very similar ( 35 s, Table 2), indicating that
the overall structure of these mutants is close to that of wild
type. The above results show that the wild-type and the mutant
helicases fold into similar 3D structures.
Zinc binding domain and DNA binding
Having established that the wild-type and mutant proteins
display the same afﬁnity for ATP and are folded similarly,
we then characterized the DNA binding activity of the wild-
type and mutant BLM helicases, using the electrophoretic
mobility shift assay. Compared with the DNA binding ability
of the wild-type BLM, that of the mutant proteins is severely
modiﬁed. As shown in Figure 9A, the C1055N mutant and the
C1055N/C1063N double mutant display severely reduced, but
still detectable, DNA binding activities. In addition, the DNA
binding activity of the C1063N mutant is completely com-
promised. From the above observation, namely that the
C1063N mutant displays a detectable ATPase activity, we
reasoned that the C1063N mutant could retain a weak DNA
binding activity, but not strong enough to be detected by
electrophoresis mobility shift assays. The apparent Kd values
of both wild-type and mutant proteins were thus determined
under equilibrium conditions, using ﬂuorescence anisotropy
assays (25). Figure 9B shows that all the mutants display a
reduction in their afﬁnity for DNA compared to the wild-type
BLM, the values ranging from  2.6-fold decrease (in apparent
Kd) for the C1055N/C1063N mutant to >7-fold decrease for
the C1063N mutant. The above results suggest that the zinc
binding domain plays an important role for DNA binding of
BLM. Previous experiments have shown that G-quadruplex
DNA (G4 DNA) is a preferred substrate over canonical
Watson–Crick duplexes for BLM (9). To investigate whether
the zinc binding domain is involved in G4 DNA recognition
and binding, we compared the binding of the wild-type and the
mutant proteins to G4 DNA. Figure 10 shows that the binding
of the mutants is severely impaired when compared with that
of the wild-type BLM. Interestingly, while the binding activity
of the mutant C1055N for the duplex DNA is only reduced, it
is almost abrogated for the G4 DNA, indicating that the zinc
binding domain plays an important role in the speciﬁc binding
of BLM to G4 DNAs. These data allow us to conclude that the
zinc binding domain is strongly involved in DNA binding, and
especially in G4 DNA binding.
DISCUSSION
Our data demonstrate that the evolutionarily conserved RecQ-
Ct region of BLM forms a zinc binding domain. We present
also evidence that the zinc binding domain plays an essential
role in DNA binding, protein stability and protein folding.
These observations shed light on the question of how some
missense mutations can lead to the destabilization of the gen-
ome and ultimately to tumorigenesis, and provide an explana-
tion of the molecular basis of BS pathogenesis.
BLM harbours a zinc binding domain
Zinc binding domains are abundant in the genomes of euka-
ryotic organisms. It is estimated that  3% of all human gene
products contain one or more zinc-binding domains or zinc
ﬁngers. They are known to be involved in protein–DNA inter-
actions, protein–protein interactions, as well as protein folding
Figure 8. StructuralcharacterizationofthemutantBLMs.(A)NormalizedCD
spectra of wild-type and different mutant BLMs (indicated in the figure). The
experimentswereperformedasdescribedunderMaterialsandMethods.About
8mMofeachproteinwasusedinthisexperiment.Allofthespectraaregivenin
units of MRE. (B) Analysis of wild-type and mutant BLM proteins by size
exclusion chromatography. Experiments were performed at room temperature
using a Superdex 200 column. Shown are the elution profiles of wild-type and
mutant proteins as indicated in the figures. About 5 mM protein was used for
each experiment. Insert: The molecular weight calibration to the partition
coefficient Kav, using protein molecular weight standards (closed circle), as
indicated under Materials and Methods. The open symbols indicate the posi-
tions of wild-type and mutants proteins.
3120 Nucleic Acids Research, 2005, Vol. 33, No. 10Figure 9. (A) AnalysesofDNA bindingactivityofwild-typeandmutantBLMsusingelectrophoreticmobilityshiftassay.Onenanomoleof50-end-labelledduplex
DNA was incubated at room temperature for 20 min with different concentration of the proteins varying from 2.5 to 2000 nM in unwinding buffer. Bound and
free DNA were separated by electrophoresis through a non-denaturing 15% polyacrylamide gel and visualized by autoradiograph. The C represents the wild-type
control.(B)DNAbindingtothewild-type(circle)andmutantproteins(C1050N,square;C1063Ntriangle;C1055N/C1063N,rhombus)underequilibriumcondition.
The anisotropy based binding isotherms were obtained upon titration of the 30-fluorescence-labelled DNA substrate which is identical to the DNA used in
radiometric assay, except it is not 50-
32P-end-labelled. The DNA binding isotherms were fitted to a Michaelis–Menten equation. The apparent Km values are
presented in Table 2.
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may contain a protein sequence reminiscent of a zinc ﬁnger
DNA binding domain (20). This suggestion became more
persuasive when a zinc binding domain was identiﬁed in
the C-terminal domain of E.coli RecQ helicase, a domain
conserved by sequence homology in BLM (21). However,
direct experiments designed to conﬁrm the existence of such
a zinc binding domain and to explore its function in BLM were
still lacking. In this study, a combination of molecular mod-
elling, site-directed mutagenesis, and biochemical and bio-
physical analyses indicate that the BLM RecQ-Ct domain
harbours a functional zinc binding domain. Theoretical pre-
diction suggested the potential of this region to form a tightly
folded zinc binding module. This theoretical consideration
provides a structural rationale for exploring the function of
the zinc binding domain in BLM. Although only X-ray crys-
tallography and/or multidimensional NMR spectroscopy can
precisely deﬁne the details of the 3D structure of this motif,
the lines of evidence reported here conﬁrm that the zinc ion is
ligated by four conserved cysteines. (i) The PAR assay clearly
shows that the zinc ion binds to BLM in a stoichiometric
fashion. (ii) Comparison of the solvent-accessible thiol groups
in the fully zinc-metalated and the zinc-demetalated proteins
indicates that the zinc atom binding site is comprised of four
cysteines. (iii) Site-directed mutagenesis studies conﬁrm that
the four cysteine residues are implicated in binding the zinc
ion. In addition, a careful analysis of the zinc-demetalated
BLM indicated that the zinc ion is not directly implicated
in ATPase, helicase or DNA binding activities. However,
this ion appears very important for the precise folding of
the zinc binding domain and consequently for maintaining
protein stability. Once the protein is correctly folded, the pres-
ence of the zinc ion is not absolutely required for the
enzymatic activities but is required for protein structure
stability. This agrees with the previous observation that
metal ions play an essential role in the protein folding process
for the formation of secondary and tertiary structures, whereas
the demetalated proteins still keep a well-deﬁned tertiary
structure and function (48).
Functional significance of the zinc binding
domain in BLM
The functional importance of the zinc binding domain was
evaluated by comprehensive site-directed mutagenesis, and
by biochemical and biophysical approaches. Altering one of
the four conserved cysteines was found to severely reduce or
abrogate ATPase and helicase activities. There are several
possible explanations for these defects. First, alteration of
one of the four cysteine residues may impair ATP binding,
leading to a loss in enzymatic activity. This possibility is
excluded by our ATP binding studies. Moreover, UV cross-
linking experiments showed that the mutant proteins were as
efﬁciently labelled as the wild-type enzyme. This was con-
ﬁrmed by quantitative binding studies performed under equi-
librium conditions, where both mutant and wild-type enzymes
displayed very similar apparent Kd values for mantATP. An
alternative possibility is that the alteration of the cysteine
residues implicated in the zinc binding domain provokes an
overall conformational change resulting in the observed
defects in the enzymatic activities. However, both CD and
size-exclusion chromatography data indicated that mutations
do not entail gross conformational changes. The other possib-
ility would be that these mutations lead to subtle and localized
conformational changes, these being sufﬁcient to result in loss
of DNA binding activities. We observed that the DNA binding
abilities of the mutants are severely reduced or almost abol-
ished when one of the four cysteine residues was altered. Since
the BLM helicase is a DNA-stimulated ATPase and ATP-
dependent helicase, it appears that the defect of DNA binding
could be the primary effect of the mutations. We therefore
conclude that the zinc binding domain of BLM is strongly
involved in DNA binding.
Two hypotheses can be put forward to explain how the zinc
binding domain is implicated in DNA binding. First, the zinc
binding domain could directly contact the DNA. Our modelled
BLM structure shows that the zinc binding domain is folded
into ﬁve a-helices, which are tightly packed together. In this
deﬁned structure, some residues could have a spatial conﬁg-
uration allowing a direct interaction with DNA. Alternatively,
the zinc binding domain could also be indirectly implicated in
the DNA binding. According to our modelled BLM structure
and the E.coli RecQ helicase crystal structure, the zinc binding
domain separates the helicase core and the C-terminal domain
which has been suggested to play a role in DNA binding. As
the helicase core is essential for the unwinding activity, it must
also be involved in DNA binding. The interplay between the
helicase domain and the C-terminal domain may be ﬁnely
tuned by the zinc binding domain to ensure a precise DNA
binding. Therefore, the mutations performed in the zinc
binding domain could alter the relative orientation of these
domains and may consequently have indirect but profound
effects on DNA binding.
However, ensuring correct protein folding could be another
potential function of the zinc binding domain of BLM. It is
Figure 10. G-quartet DNA binding activity for BLM protein is severely
impaired upon the zinc binding domain mutations. Two nanomoles 50-
fluorescein labelled G4 DNA and duplex DNA were titrated with the wild-
type BLM (open and closed circle, respectively) and the mutated enzymes
(C1063N, triangle; C1055N, square; C1055N/C1063N, rhombus) under
the same experimental conditions as indicated in Figure 9B. Note that while
the wild-type BLM displays higher affinity for G4 DNA over the duplex DNA
(Figure 9B), the binding affinity for G4 DNA is greatly reduced for the three
mutants, especially for the C1055N mutant (square).
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domain could not be puriﬁed due to extensive proteolytic
degradation. In this way, the alteration of the conserved
cysteine residues could lead to an incorrectly folded or par-
tially denatured protein that is very sensitive to protease
degradation. These observations are reminiscent of E.coli
RecQ helicase and are coincident with the observations
by Janscak et al. (34), showing that all the three cysteine
to alanine mutants they made displayed a high level of sus-
ceptibility to proteolytic degradation (23). The zinc binding
domain may function in the BLM folding cascade, favouring
the link between the domains and the stabilization of the
protein’s conformation. Furthermore, Janscak et al. also
observed that the replacement of D1064 by alanine entailed
a dramatic reduction of both DNA binding and helicase activ-
ity, while replacement of D1064 with asparagine kept the
properties of the mutant similar to the wild type, in terms
of DNA binding and helicase activity. These observations
are also consistent with our theoretical BLM model which
shows that the hydrogen bonds between R1037 and D1064
are crucial for stabilizing the structure of the zinc binding
domain, and therefore the whole protein structure. Replace-
ment of Asp-1064 with the non-polar residue alanine should
certainly completely disrupt the interactions between residues
1037 and 1064. In accordance with this reasoning, the replace-
ment of R1037 with alanine in our studies resulted in protein
degradation even in the presence of protease inhibitors, sug-
gesting that the hydrogen bond between R1037 and D1064
plays an important role in the conformational stabilization of
BLM. Moreover, the mutant R1038A exhibits very low activ-
ities in both DNA binding and DNA unwinding (34). These
results indicate that, in addition to the four cysteine residues, a
cluster of amino acids in the zinc binding domain could par-
ticipate to the stabilization of the protein structure. Thus, the
zinc binding domain of BLM appears to play a dual role in
maintaining the structural and functional integrity of the BLM
protein and in playing a pivotal role in DNA binding.
Implication for pathology
Many of the mutations found hitherto at the BLM locus that
are associated with BS either create a stop codon mutation or
cause a frame shift that leads to premature termination, which
are predicted to eliminate the function of one or more of the
helicase motifs. However, there are two point mutations
mapping to Cys-1036 and Cys-1055, which lie outside of
the conserved helicase motifs. Is it possible that these two
point mutations also inactivate the helicase function of BLM
or severely impair its enzymatic activities? To address these
questions, we produced the two disease-linked missense muta-
tions found in patients, C1036F and C1055S. One of these
mutant proteins, C1055S, was completely degraded before the
puriﬁcation step and the other one, C1036F, precipitated dur-
ing the biosynthesis, by forming an inclusion body (Table 2).
Therefore, it was not possible to further characterize these
mutations directly. However, a previous study on the murine
C1063S mutant BLM has shown it to be defective in helicase
and ATPase activities (46). Another study performed with
human BLM has shown that the cells expressing the
C1055S allele present a diffuse nuclear distribution of this
missense BLM as well as a severe reduction in both helicase
and ATPase activities (47). These results, together with the
above observations, shed light on the molecular basis of the
two disease-linked BLM missense mutations. First, it seems
possible that these mutations severely modify the 3D structure
of the protein, resulting in its degradation or precipitation,
and therefore the abrogation of all the enzymatic activities.
Second, it is possible that, in the human cell context, the
mutant proteins could exist assoluble proteindue tochaperone
or protein–protein interactions. However, as shown above,
the soluble mutants resulting from altered cysteine residues
display drastically reduced or completely abolished DNA
binding and enzymatic activities. Finally, the combination
of the above-mentioned events could lead to the disease.
This alteration of the zinc binding domain should dramatically
modify the protein structure and function, leading to BS.
Previous studies have shown that mutations or deletions in
the C-terminal part of BLM have a dominant negative effect
on the SCE frequency and cause an increase in chromosome
abnormalities (15). The data presented in this paper further
emphasize the importance of the C-terminal domain in BLM
function,includingDNAbinding.TheC-terminaldomainmay
confer BLM the ability to recognize and bind abnormal DNA
structures such as quadruplexes (G4 DNA) (9). This is con-
sistent with our observation that some mutations in the zinc
binding domain completely impair the binding to G4 DNA
while binding to the duplex DNA is still detectable. The pos-
sible direct implication of the zinc binding domain in the
binding of BLM to the G4 DNA is currently under investiga-
tion in our laboratory.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at NAR Online.
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